Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
AMB Express
2014 Oct 31;4:78. doi: 10.1186/s13568-014-0078-z.
Show Gene links
Show Anatomy links
Paracentrin 1, a synthetic antimicrobial peptide from the sea-urchin Paracentrotus lividus, interferes with staphylococcal and Pseudomonas aeruginosa biofilm formation.
Schillaci D
,
Cusimano MG
,
Spinello A
,
Barone G
,
Russo D
,
Vitale M
,
Parrinello D
,
Arizza V
.
???displayArticle.abstract???
The rise of antibiotic-resistance as well as the reduction of investments by pharmaceutical companies in the development of new antibiotics have stimulated the investigation for alternative strategies to conventional antibiotics. Many antimicrobial peptides show a high specificity for prokaryotes and a low toxicity for eukaryotic cells and, due to their mode of action the development of resistance is considered unlikely. We recently characterized an antimicrobial peptide that was called Paracentrin 1 from the 5-kDa peptide fraction from the coelomocyte cytosol of the Paracentrotus lividus. In this study, the chemically synthesized Paracentrin 1, was tested for its antimicrobial and antibiofilm properties against reference strains of Gram positive and Gram negative. The Paracentrin 1 was active against planktonic form of staphylococcal strains (reference and isolates) and Pseudomonas aeruginosa ATCC 15442 at concentrations ranging from 12.5 to 6.2 mg/ml. The Paracentrin 1 was able to inhibit biofilm formation of staphylococcal and Pseudomonas aeruginosa strains at concentrations ranging from 3.1 to 0.75 mg/ml. We consider the tested peptide as a good starting molecule for novel synthetic derivatives with improved pharmaceutical potential.
Figure 1. Example of MD simulation box, showing the SP1 molecule, the solution counterions, Na
+
(in blue) and Cl
â
(in cyan), and the explicit water molecules (in red).
Figure 2. Plot of the RMSD obtained for SP1 up to 400Â ns of MD simulation.
Figure 3. Ramachandran plot showing the values of psi and phi angles assumed by residues 2â10 of SP1 between 150 and 250Â ns of the MD simulation.
Figure 4. Molecular representation of SP1 at about 200Â ns of MD showing the non amphipathic structure of the peptide. The potential surface is superimposed. Color code: acidic residues in red, basic residues in blue, and hydrophobic residues in yellow.
Figure 5. Interference with biofilm formation of SP1 against reference staphylococcal andP. aeruginosastrains. The percentage of inhibition were evaluated comparing the samples with not-treated 24 h old biofilms and staining with safranin. Bacterial strains () S. aureus 25923, () S. aureus 29213, () S. aureus 6538, () S. epidermidis RP62A, () P. aeruginosa 15442. Data for each strain are the mean of three distinct experimentsâ±âS.D.
Figure 6. SEM micrography showing the effect of sub-MIC concentration of SP1 onS. epidermidisRP62A biofilm formation. A) Growth control (not treated with SP1); B) sample treated with a sub-MIC concentration (3.1Â mg/ml) of SP1.
Figure 7. Hemolytic activity of SP1 peptides fromParacentrotus lividushemocytes against rabbit blood cells at different concentrations: 1.5 mg/ml; 3.2 mg/ml; 6.2 mg/ml; 50 mg/ml. Data are the mean value of three separate experiments and expressed as percentage of hemolysisâ±âSD
Andreu,
Animal antimicrobial peptides: an overview.
1998, Pubmed
Andreu,
Animal antimicrobial peptides: an overview.
1998,
Pubmed
Arizza,
Gender differences in the immune system activities of sea urchin Paracentrotus lividus.
2013,
Pubmed
,
Echinobase
Arizza,
A lytic mechanism based on soluble phospholypases A2 (sPLA2) and β-galactoside specific lectins is exerted by Ciona intestinalis (ascidian) unilocular refractile hemocytes against K562 cell line and mammalian erythrocytes.
2011,
Pubmed
Auvynet,
Structural requirements for antimicrobial versus chemoattractant activities for dermaseptin S9.
2008,
Pubmed
Bax,
The millennium bugs--the need for and development of new antibacterials.
2000,
Pubmed
Brogden,
Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?
2011,
Pubmed
Chan,
Helix induction in antimicrobial peptides by alginate in biofilms.
2004,
Pubmed
Clutterbuck,
Biofilms and their relevance to veterinary medicine.
2007,
Pubmed
de Andrade,
Antimicrobial activity and synergism of lactoferrin and lysozyme against cariogenic microorganisms.
2014,
Pubmed
Fischer,
In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis.
2003,
Pubmed
Gautier,
HELIQUEST: a web server to screen sequences with specific alpha-helical properties.
2008,
Pubmed
Gilbert,
Biofilms in vitro and in vivo: do singular mechanisms imply cross-resistance?
2002,
Pubmed
Hancock,
Role of membranes in the activities of antimicrobial cationic peptides.
2002,
Pubmed
Hancock,
Peptide antibiotics.
1999,
Pubmed
Hancock,
Cationic peptides: effectors in innate immunity and novel antimicrobials.
2001,
Pubmed
Hancock,
Peptide antibiotics.
1997,
Pubmed
Hancock,
Cationic peptides: a new source of antibiotics.
1998,
Pubmed
Huang,
Alpha-helical cationic antimicrobial peptides: relationships of structure and function.
2010,
Pubmed
Huang,
Action of antimicrobial peptides: two-state model.
2000,
Pubmed
Lamazière,
Non-metabolic membrane tubulation and permeability induced by bioactive peptides.
2007,
Pubmed
Lauria,
Nickel(II), copper(II) and zinc(II) metallo-intercalators: structural details of the DNA-binding by a combined experimental and computational investigation.
2014,
Pubmed
Lentini,
Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay.
2014,
Pubmed
Lequin,
Dermaseptin S9, an alpha-helical antimicrobial peptide with a hydrophobic core and cationic termini.
2006,
Pubmed
Li,
Centrocins: isolation and characterization of novel dimeric antimicrobial peptides from the green sea urchin, Strongylocentrotus droebachiensis.
2010,
Pubmed
,
Echinobase
Lindorff-Larsen,
Improved side-chain torsion potentials for the Amber ff99SB protein force field.
2010,
Pubmed
Liu,
Guidelines for membrane protein engineering derived from de novo designed model peptides.
1998,
Pubmed
Matsuzaki,
Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes.
1999,
Pubmed
Matsuzaki,
Magainins as paradigm for the mode of action of pore forming polypeptides.
1998,
Pubmed
Melchior,
Biofilms: a role in recurrent mastitis infections?
2006,
Pubmed
Melchior,
Biofilm formation and genotyping of Staphylococcus aureus bovine mastitis isolates: evidence for lack of penicillin-resistance in Agr-type II strains.
2009,
Pubmed
Mor,
The NH2-terminal alpha-helical domain 1-18 of dermaseptin is responsible for antimicrobial activity.
1994,
Pubmed
Oren,
Mode of action of linear amphipathic alpha-helical antimicrobial peptides.
1998,
Pubmed
Patel,
Biofilms and antimicrobial resistance.
2005,
Pubmed
Projan,
Antimicrobials: new solutions badly needed.
2002,
Pubmed
Pronk,
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.
2013,
Pubmed
Schillaci,
3,4,5,3',5'-Pentabromo-2-(2'-hydroxybenzoyl)pyrrole: a potential lead compound as anti-Gram-positive and anti-biofilm agent.
2005,
Pubmed
Schillaci,
Fragments of β-thymosin from the sea urchin Paracentrotus lividus as potential antimicrobial peptides against staphylococcal biofilms.
2012,
Pubmed
,
Echinobase
Schillaci,
Immune mediators of sea-cucumber Holothuria tubulosa (Echinodermata) as source of novel antimicrobial and anti-staphylococcal biofilm agents.
2013,
Pubmed
,
Echinobase
Schillaci,
Antimicrobial and antistaphylococcal biofilm activity from the sea urchin Paracentrotus lividus.
2010,
Pubmed
,
Echinobase
Schumacher-Perdreau,
Comparative analysis of a biofilm-forming Staphylococcus epidermidis strain and its adhesion-positive, accumulation-negative mutant M7.
1994,
Pubmed
Shai,
Mode of action of membrane active antimicrobial peptides.
2002,
Pubmed
Shai,
Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides.
1999,
Pubmed
Sitaram,
The therapeutic potential of host-defense antimicrobial peptides.
2002,
Pubmed
Skerlavaj,
Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities.
1996,
Pubmed
Stabili,
Antibacterial protection in Marthasterias glacialis eggs: characterization of lysozyme-like activity.
1994,
Pubmed
,
Echinobase
Stark,
Cationic hydrophobic peptides with antimicrobial activity.
2002,
Pubmed
Storici,
Chemical synthesis and biological activity of a novel antibacterial peptide deduced from a pig myeloid cDNA.
1994,
Pubmed
Tossi,
Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes.
1994,
Pubmed
Turner,
Precise quantitative determination of human blood lipids by thin-layer and triethylaminoethylcellulose column chromatography. I. Erythrocyte lipids.
1970,
Pubmed
Verkleij,
The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy.
1973,
Pubmed
Wang,
APD2: the updated antimicrobial peptide database and its application in peptide design.
2009,
Pubmed
Wang,
APD: the Antimicrobial Peptide Database.
2004,
Pubmed
Wu,
Selective toxicity of antimicrobial peptide S-thanatin on bacteria.
2010,
Pubmed
Zasloff,
Antimicrobial peptides of multicellular organisms.
2002,
Pubmed